Fluconazole (Paediatric)
Brand names: Diflucan
Paediatric use of fluconazole, a triazole antifungal, for candidal and other susceptible fungal infections including mucosal candidiasis and cryptococcal disease in children and neonates.
Adult dose
Paediatric dose
Dose adjustments
Fluconazole is predominantly excreted in the urine as unchanged active substance. 'No adjustments in single dose therapy are necessary.' For patients (including the paediatric population) with impaired renal function receiving multiple doses, give an initial dose of 50 mg to 400 mg based on the recommended daily dose for the indication, then adjust the daily dose: creatinine clearance above 50 ml/min — 100% of the recommended dose; 50 ml/min or below (no haemodialysis) — 50%; haemodialysis — 100% of the recommended dose after each haemodialysis session, with a reduced dose according to creatinine clearance on non-dialysis days.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, to related azole substances, or to any of the excipients
- Co-administration of terfenadine in patients receiving fluconazole at multiple doses of 400 mg per day or higher
- Co-administration of other medicinal products known to prolong the QT interval and metabolised via cytochrome P450 (CYP) 3A4, such as cisapride, astemizole, pimozide, quinidine and erythromycin
Side effects
- Headache (common); somnolence, insomnia, dizziness, paraesthesia, taste perversion and seizures (uncommon)
- Abdominal pain, vomiting, diarrhoea and nausea (common); constipation, dyspepsia, flatulence and dry mouth (uncommon)
- Raised alanine aminotransferase, aspartate aminotransferase and blood alkaline phosphatase (common); cholestasis, jaundice and raised bilirubin (uncommon); hepatic failure, hepatocellular necrosis, hepatitis and hepatocellular damage (rare)
- Rash (common); drug eruption, urticaria, pruritus and increased sweating (uncommon); toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS)
- Torsade de pointes and QT prolongation (rare); anaemia (common), with agranulocytosis, leukopenia, thrombocytopenia and neutropenia (uncommon); anaphylaxis (uncommon)
Interactions
- Terfenadine — co-administration contraindicated at fluconazole multiple doses of 400 mg/day or higher (§4.3)
- Cisapride, astemizole, pimozide, quinidine and erythromycin — QT-prolonging CYP3A4-metabolised medicines; co-administration contraindicated (§4.3)
- Other QT-prolonging medicinal products such as amiodarone — 'The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4' (§4.4)
- Oral contraceptives — after fluconazole 200 mg daily, mean AUC increases of about 25% for levonorgestrel and about 38% for ethinyl estradiol versus placebo, both statistically significant (US label drug interaction study)
- NOTE: SPC §4.5 ('The effect of fluconazole on other medicinal products') was NOT retrieved in full in this source bundle — the clinician must verify the complete interaction list before publishing
Clinical monograph
How it works
Inhibits fungal cytochrome P450-dependent 14-alpha-demethylase, blocking conversion of lanosterol to ergosterol and disrupting fungal cell membrane integrity.
Prescribing in practice
- Dosing in children and neonates differs markedly by age and renal function and must be confirmed against a children's formulary; neonatal clearance is prolonged so dosing intervals are extended.
- It is a potent enzyme inhibitor (notably CYP2C9 and CYP3A4) and prolongs the QT interval, so review concurrent medicines for interaction and arrhythmia risk.
- Adjust dosing in renal impairment and monitor liver function with prolonged or higher-dose courses.
Monitoring
Monitor liver function during prolonged therapy and assess renal function, with ECG consideration where additional QT-prolonging factors or drugs are present.
Counselling the patient
- Tell the team about any other medicines, as fluconazole interacts with many drugs.
- Report jaundice, dark urine, persistent nausea or rash to a clinician.
- Complete the full prescribed course even once the child feels better.
Evidence & guidelines
Fluconazole is an established antifungal supported by SPC and paediatric infectious disease guidance for candidal and cryptococcal infection.
Reference: ESCMID Candida Guidelines; BPNG Neonatal Antifungal Guidelines; NICE Preterm Birth Guidance NG25; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.